AllAnalyst Report
logoMorningstarMay 13, 2021

AbbVie Inc.: AbbVie Posts Solid Q1 as New Drugs Look Increasingly Well Positioned to Mitigate Humira Generics

Symbols
ABBV
Sector(s)
Healthcare
Rating
Current Price
$114.00
Fair Value
Economic Moat
Stewardship
Summary

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

Damien Conover

Sector Director
Damien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.